RTF2

Replication termination factor 2 · Q9BY42 · RTF2 on Sugi Atlas →

0 patent compounds predicted against RTF2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RTF2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. PHASE2COMPLETED
Danazol for Treatment of Cytopenias in Patients With Cirrhosis PHASE2RECRUITING
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection nanUNKNOWN
Susceptibility to Infections in Ataxia Telangiectasia nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2) nanACTIVE_NOT_RECRUITING
Epidemiological and Genetic Studies of Body Mass Index nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma nanCOMPLETED
Body Awareness and Aerobic Exercise: Telomere Impact nanCOMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Uncovering the Etiologies of Non-immune Hydrops Fetalis nanENROLLING_BY_INVITATION
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RTF2 binder may also engage these)

ProteinNameSimilarity
Q5R9P9 1.000 Q5R9P9 →
Q3T1J8 1.000 Q3T1J8 →
Q0VCR1 1.000 Q0VCR1 →
Q4R594 1.000 Q4R594 →
A5GFW7 1.000 A5GFW7 →
Q99K95 1.000 Q99K95 →
Q5ZJN1 1.000 Q5ZJN1 →
Q10154 0.988 Q10154 →
Q21755 0.987 Q21755 →
Q28E45 0.986 Q28E45 →
Q5EAW4 0.985 Q5EAW4 →
E1C760 0.984 E1C760 →
F7AEX0 0.983 F7AEX0 →
Q9SY88 0.983 Q9SY88 →
Q66I85 0.982 Q66I85 →
O59800 0.982 O59800 →
Q9D516 0.982 Q9D516 →
P28518 0.981 P28518 →
Q8IZP6 0.981 Q8IZP6 →
RFC1 Replication factor C subunit 1 0.981 landscape →
Q7SH49 0.981 Q7SH49 →
Q9M358 0.981 Q9M358 →
P35728 0.981 P35728 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.981 landscape →
Q3SZM1 0.981 Q3SZM1 →
Q6C3L4 0.981 Q6C3L4 →
Q640E9 0.981 Q640E9 →
Q8BP78 0.980 Q8BP78 →
A6ZPY2 0.980 A6ZPY2 →
Q9VIE6 0.980 Q9VIE6 →